TWI706937B - 製備蛋白質去乙醯酶抑制劑之方法 - Google Patents

製備蛋白質去乙醯酶抑制劑之方法 Download PDF

Info

Publication number
TWI706937B
TWI706937B TW105118213A TW105118213A TWI706937B TW I706937 B TWI706937 B TW I706937B TW 105118213 A TW105118213 A TW 105118213A TW 105118213 A TW105118213 A TW 105118213A TW I706937 B TWI706937 B TW I706937B
Authority
TW
Taiwan
Prior art keywords
compound
acid
reacting
preparing
specific embodiment
Prior art date
Application number
TW105118213A
Other languages
English (en)
Chinese (zh)
Other versions
TW201718517A (zh
Inventor
法薩尼 賽迪
杜瑟 約翰Ｈ 凡
Original Assignee
美商艾斯特隆製藥公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商艾斯特隆製藥公司 filed Critical 美商艾斯特隆製藥公司
Publication of TW201718517A publication Critical patent/TW201718517A/zh
Application granted granted Critical
Publication of TWI706937B publication Critical patent/TWI706937B/zh

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/30—Halogen atoms or nitro radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
TW105118213A 2015-06-08 2016-06-08 製備蛋白質去乙醯酶抑制劑之方法 TWI706937B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562172624P 2015-06-08 2015-06-08
US62/172,624 2015-06-08

Publications (2)

Publication Number Publication Date
TW201718517A TW201718517A (zh) 2017-06-01
TWI706937B true TWI706937B (zh) 2020-10-11

Family

ID=56264043

Family Applications (1)

Application Number Title Priority Date Filing Date
TW105118213A TWI706937B (zh) 2015-06-08 2016-06-08 製備蛋白質去乙醯酶抑制劑之方法

Country Status (11)

Country Link
US (1) US10144714B2 (enExample)
EP (1) EP3303304B1 (enExample)
JP (1) JP6873053B2 (enExample)
CN (1) CN107922352B (enExample)
AR (1) AR105812A1 (enExample)
AU (2) AU2016276573A1 (enExample)
CA (1) CA2988594C (enExample)
ES (1) ES2769255T3 (enExample)
MX (1) MX369349B (enExample)
TW (1) TWI706937B (enExample)
WO (1) WO2016200930A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2526093T3 (pl) * 2010-01-22 2017-02-28 Acetylon Pharmaceuticals, Inc. Odwrócone związki amidowe jako inhibitory deacetylazy białkowej oraz sposoby ich stosowania
EP2839037B1 (en) 2012-04-19 2018-12-26 Acetylon Pharmaceuticals, Inc. Biomarkers to identify patients that will respond to treatment and treating such patients
WO2016200930A1 (en) 2015-06-08 2016-12-15 Acetylon Pharmaceuticals, Inc. Methods of making protein deacetylase inhibitors
US10464906B2 (en) 2015-06-08 2019-11-05 Acetylon Pharmaceuticals, Inc. Crystalline forms of a histone deacetylase inhibitor
JP7233220B2 (ja) * 2016-06-09 2023-03-06 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド Ｈｄａｃ阻害剤とｂｅｔ阻害剤の使用方法及びその薬学的組み合わせ
WO2018031472A1 (en) 2016-08-08 2018-02-15 Acetylon Pharmaceuticals Inc. Pharmaceutical combinations of histone deacetylase 6 inhibitors and cd20 inhibitory antibodies and uses thereof
JP7090611B2 (ja) 2016-11-23 2022-06-24 アセチロン ファーマシューティカルズ インコーポレイテッド ヒストン脱アセチル化酵素阻害剤とプログラム細胞死リガンド１（ｐｄ－ｌ１）阻害剤とを含む医薬組み合わせ物及びその使用方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015054099A1 (en) * 2013-10-08 2015-04-16 Acetylon Pharmaceuticals, Inc. Combinations of histone deacetylase inhibitors and either her2 inhibitors or pi3k inhibitors

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6777217B1 (en) 1996-03-26 2004-08-17 President And Fellows Of Harvard College Histone deacetylases, and uses related thereto
US20030129724A1 (en) 2000-03-03 2003-07-10 Grozinger Christina M. Class II human histone deacetylases, and uses related thereto
ATE489360T1 (de) 2000-03-24 2010-12-15 Methylgene Inc Inhibitoren der histon-deacetylase
US20050119305A1 (en) 2001-03-21 2005-06-02 Masao Naka Il-6 production inhibitors
US7244853B2 (en) 2001-05-09 2007-07-17 President And Fellows Of Harvard College Dioxanes and uses thereof
WO2003037869A1 (en) 2001-11-01 2003-05-08 Janssen Pharmaceutica N.V. Amide derivatives as glycogen synthase kinase 3-beta inhibitors
US7154002B1 (en) 2002-10-08 2006-12-26 Takeda San Diego, Inc. Histone deacetylase inhibitors
EP1608628A2 (en) 2003-03-17 2005-12-28 Takeda San Diego, Inc. Histone deacetylase inhibitors
EP1644323B1 (en) 2003-07-07 2015-03-18 Georgetown University Histone deacetylase inhibitors and methods of use thereof
CN101010298A (zh) 2004-04-05 2007-08-01 默克Hdac研究有限责任公司 组蛋白脱乙酰酶抑制剂前药
EP1861126A4 (en) 2005-03-22 2009-11-18 Harvard College TREATMENT OF PROTEIN REMOVAL TROUBLES
KR20080052611A (ko) 2005-08-26 2008-06-11 메틸진 인크. 히스톤 탈아세틸 효소의 벤조디아제핀 및 벤조피페라진유도체 억제제
EP1991247B1 (en) 2006-02-14 2015-10-14 President and Fellows of Harvard College Bifunctional histone deacetylase inhibitors
EP2019674B1 (en) 2006-05-03 2016-11-23 The President and Fellows of Harvard College Histone deacetylase and tubulin deacetylase inhibitors
US20100278782A1 (en) 2006-06-12 2010-11-04 Vrije Universiteit Brussel Differentiation of rat liver epithelial cells into hepatocyte-like cells
ES2288802B1 (es) 2006-07-07 2008-12-16 Universidad De Granada Nuevos derivados de ftalimida como inhibidores de las histonas desacetilasas.
US7888361B2 (en) 2006-09-11 2011-02-15 Curis, Inc. Tyrosine kinase inhibitors containing a zinc binding moiety
WO2009104696A1 (ja) 2008-02-19 2009-08-27 株式会社アーネストメディスン 身体機能の回復に有用な経口又は経腸組成物
CN102164888B (zh) 2008-07-23 2015-06-03 哈佛大学校长及研究员协会 脱乙酰酶抑制剂和其用途
US8716326B2 (en) 2009-05-15 2014-05-06 Korea Research Institute Of Chemical Technology Isoindolinone derivatives, preparation method thereof and a pharmaceutical composition comprising same
WO2011019393A2 (en) 2009-08-11 2011-02-17 President And Fellows Of Harvard College Class- and isoform-specific hdac inhibitors and uses thereof
US8759366B2 (en) * 2009-12-17 2014-06-24 Merck Sharp & Dohme Corp. Aminopyrimidines as SYK inhibitors
EP2638009A4 (en) 2010-01-08 2014-06-11 Harvard College FLUORINATED HDAC HEMMER AND USES THEREOF
PL2526093T3 (pl) 2010-01-22 2017-02-28 Acetylon Pharmaceuticals, Inc. Odwrócone związki amidowe jako inhibitory deacetylazy białkowej oraz sposoby ich stosowania
WO2011146855A1 (en) 2010-05-21 2011-11-24 The Trustees Of Columbia University In The City Of New York Selective hdac inhibitors
WO2012018499A2 (en) 2010-08-05 2012-02-09 Acetylon Pharmaceuticals Specific regulation of cytokine levels by hdac6 inhibitors
AU2011329028B2 (en) 2010-11-16 2016-12-22 Acetylon Pharmaceuticals, Inc. Pyrimidine hydroxy amide compounds as protein deacetylase inhibitors and methods of use thereof
EP2734500A4 (en) 2011-07-20 2015-04-08 Gen Hospital Corp SELECTIVE HISTONDEACETYLASE-6 INHIBITORS FOR THE TREATMENT OF BONE DISORDERS
WO2013048949A2 (en) * 2011-09-26 2013-04-04 Bristol-Myers Squibb Company Selective nr2b antagonists
JP5724851B2 (ja) * 2011-11-30 2015-05-27 東レ株式会社 Ｎ−（ヨードフェニル）ピリミジニルアミン誘導体の製造方法
EP2839037B1 (en) 2012-04-19 2018-12-26 Acetylon Pharmaceuticals, Inc. Biomarkers to identify patients that will respond to treatment and treating such patients
EP2906211A4 (en) 2012-10-12 2016-04-20 Univ Pennsylvania PYRIMIDINHYDROXY AMID COMPOUNDS AS A PROTEIN DEACETYLASE INHIBITOR AND METHOD OF USE THEREOF
US9145412B2 (en) 2012-11-02 2015-09-29 Acetylon Pharmaceuticals, Inc. Selective HDAC1 and HDAC2 inhibitors
US9096549B2 (en) 2013-02-01 2015-08-04 Acetylon Pharmaceuticals, Inc. Selective HDAC3 inhibitors
US9139583B2 (en) 2013-02-01 2015-09-22 Acetylon Pharmaceuticals, Inc. Selective HDAC3 inhibitors
JP2016523236A (ja) 2013-06-03 2016-08-08 アセチロン ファーマシューティカルズ インコーポレイテッドＡｃｅｔｙｌｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． 多発性骨髄腫におけるヒストン脱アセチル化酵素（ｈｄａｃ）バイオマーカー
EP3046559A4 (en) 2013-09-20 2017-03-22 Acetylon Pharmaceuticals, Inc. Treatment of diseases caused by abnormal lymphocyte function with an hdac6 inhibitor
ES2818933T3 (es) 2013-10-10 2021-04-14 Acetylon Pharmaceuticals Inc Inhibidores de la HDAC en combinación con los inhibidores de la pi3k, para el tratamiento del linfoma no Hodgkin
EP3055299B1 (en) 2013-10-10 2021-01-06 Acetylon Pharmaceuticals, Inc. Pyrimidine hydroxy amide compounds as histone deacetylase inhibitors
WO2015054197A1 (en) 2013-10-10 2015-04-16 Acetylon Pharmaceuticals, Inc. Hdac inhibitors, alone or in combination with btk inhibitors, for treating non-hodgkin's lymphoma
JP2016532667A (ja) 2013-10-11 2016-10-20 アセチロン ファーマシューティカルズ インコーポレイテッドＡｃｅｔｙｌｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． ヒストンデアセチラーゼ阻害薬及び免疫調節薬の組み合わせ
US10660890B2 (en) 2013-10-24 2020-05-26 National Institutes Of Health (Nih), U.S. Dept. Of Health And Human Services (Dhhs), U.S. Government Nih Division Of Extramural Inventions And Technology Resources (Deitr) Treatment of polycystic diseases with an HDAC6 inhibitor
EP3076973B1 (en) 2013-12-03 2020-04-29 Acetylon Pharmaceuticals, Inc. Combinations of histone deacetylase inhibitors and immunomodulatory drugs
WO2015095632A1 (en) 2013-12-20 2015-06-25 Acetylon Pharmaceuticals, Inc. Histone deacetylase 6 (hdac6) biomarkers in multiple myeloma
US9464073B2 (en) 2014-02-26 2016-10-11 Acetylon Pharmaceuticals, Inc. Pyrimidine hydroxy amide compounds as HDAC6 selective inhibitors
US20150359794A1 (en) 2014-06-13 2015-12-17 Buck Institute For Research On Aging Impairment of the large ribosomal subunit protein rpl24 by depletion or acetylation
WO2016007423A1 (en) 2014-07-07 2016-01-14 Acetylon Pharmaceuticals, Inc. Treatment of leukemia with histone deacetylase inhibitors
US20160137630A1 (en) 2014-10-08 2016-05-19 Acetylon Pharmaceuticals, Inc. Induction of gata2 by hdac1 and hdac2 inhibitors
WO2016090230A1 (en) 2014-12-05 2016-06-09 Acetylon Pharmaceuticals, Inc. Pyrimidine hydroxy amide compounds for treating peripheral neuropathy
WO2016087950A1 (en) 2014-12-05 2016-06-09 University of Modena and Reggio Emilia Combinations of histone deacetylase inhibitors and bendamustine for use in the treatment of lymphoma
ES2816641T3 (es) 2014-12-12 2021-04-05 Regenacy Pharmaceuticals Inc Derivados de piperidina en calidad de inhibidores de HDAC1/2
WO2016168647A1 (en) 2015-04-17 2016-10-20 Acetylon Pharmaceuticals Inc. Treatment of neuroblastoma with histone deacetylase inhibotrs
US10272084B2 (en) 2015-06-01 2019-04-30 Regenacy Pharmaceuticals, Llc Histone deacetylase 6 selective inhibitors for the treatment of cisplatin-induced peripheral neuropathy
US10464906B2 (en) 2015-06-08 2019-11-05 Acetylon Pharmaceuticals, Inc. Crystalline forms of a histone deacetylase inhibitor
WO2016200930A1 (en) 2015-06-08 2016-12-15 Acetylon Pharmaceuticals, Inc. Methods of making protein deacetylase inhibitors
WO2018031472A1 (en) 2016-08-08 2018-02-15 Acetylon Pharmaceuticals Inc. Pharmaceutical combinations of histone deacetylase 6 inhibitors and cd20 inhibitory antibodies and uses thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015054099A1 (en) * 2013-10-08 2015-04-16 Acetylon Pharmaceuticals, Inc. Combinations of histone deacetylase inhibitors and either her2 inhibitors or pi3k inhibitors

Also Published As

Publication number Publication date
WO2016200930A1 (en) 2016-12-15
CA2988594C (en) 2023-08-15
US10144714B2 (en) 2018-12-04
JP6873053B2 (ja) 2021-05-19
TW201718517A (zh) 2017-06-01
AU2016276573A1 (en) 2018-01-04
MX2017015900A (es) 2018-11-09
WO2016200930A9 (en) 2017-02-23
CN107922352B (zh) 2021-08-06
EP3303304A1 (en) 2018-04-11
US20160355486A1 (en) 2016-12-08
JP2018518486A (ja) 2018-07-12
EP3303304B1 (en) 2019-11-20
AR105812A1 (es) 2017-11-15
CA2988594A1 (en) 2016-12-15
AU2020267299A1 (en) 2020-12-10
CN107922352A (zh) 2018-04-17
AU2020267299B2 (en) 2022-07-07
MX369349B (es) 2019-11-06
ES2769255T3 (es) 2020-06-25

Similar Documents

Publication Publication Date Title
TWI706937B (zh) 製備蛋白質去乙醯酶抑制劑之方法
WO2017221189A1 (en) An improved process for the preparation of tenofovir alafenamide or pharmaceutically acceptable salts thereof
KR102266680B1 (ko) 벨리노스테트의 다형태 및 이의 제조 방법
WO2014020555A2 (en) An improved process for the preparation of dabigatran etexilate mesylate
WO2013065063A1 (en) Anhydrous form of dasatinib, process for its preparation and its use
TW201718516A (zh) 組蛋白去乙醯酶抑制劑之晶形
CN117897387A (zh) Glp-1受体激动剂中间体的制备方法
US20070203176A1 (en) Crystalline forms of dolasetron base and processes for preparation thereof
WO2014096373A1 (en) Process for prepararing n-(2-(7-methoxy-1-naphthalenyl)ethyl) acetamide and solid forms thereof
US20240010632A1 (en) Solid state forms of erdafitinib salts and processes for preparation of erdafitinib
US20150315164A1 (en) Process for preparing amorphous cabazitaxel
JP7492997B2 (ja) オラパリブの製造方法
WO2015104602A2 (en) A process for the preparation of anagliptin and its intermediates thereof
JP5234856B2 (ja) Ｎｐｙｙ５受容体拮抗作用を有する化合物の結晶
CN105121417B (zh) 经取代噻唑基乙酸三乙胺盐的结晶型
JP3884063B2 (ja) セフカペンピボキシルのメタンスルホン酸塩
JP2025517548A (ja) ４－置換２－オキサゾリジノンの調製プロセス
WO2022034427A1 (en) An improved process for the preparation of 4-oxoisotretinoin
JP2010526126A (ja) バルサルタンの製造方法
JPH09328473A (ja) ３，４−ジヒドロカルボスチリルの製造方法